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Abstract
Background: Resolving the kinetic mechanisms of biomolecular interactions have become increasingly important
in early-phase drug development. Since traditional in vitro methods belong to dose-dependent assessments,
binding kinetics is usually overlooked. The present study aimed at the establishment of two novel experimental
approaches for the assessment of binding affinity of both, radiolabelled and non-labelled compounds targeting the
A3R, based on high-resolution real-time data acquisition of radioligand-receptor binding kinetics. A novel time-
resolved competition assay was developed and applied to determine the Ki of eight different A3R antagonists,
using CHO-K1 cells stably expressing the hA3R. In addition, a new kinetic real-time cell-binding approach was
established to quantify the rate constants kon and koff, as well as the dedicated Kd of the A3R agonist [
125I]-AB-MECA.
Furthermore, lipophilicity measurements were conducted to control influences due to physicochemical properties of
the used compounds.
Results: Two novel real-time cell-binding approaches were successfully developed and established. Both experimental
procedures were found to visualize the kinetic binding characteristics with high spatial and temporal resolution, resulting
in reliable affinity values, which are in good agreement with values previously reported with traditional methods. Taking
into account the lipophilicity of the A3R antagonists, no influences on the experimental performance and the resulting
affinity were investigated.
Conclusions: Both kinetic binding approaches comprise tracer administration and subsequent binding to living cells,
expressing the dedicated target protein. Therefore, the experiments resemble better the true in vivo physiological
conditions and provide important markers of cellular feedback and biological response.
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Background
Binding studies on pharmacological targets are undoubt-
edly an indispensable part in drug development, to
determine pharmacokinetic parameters of biomolecular
interactions. The reliable in vitro assessment of ligand
affinity, as well as the understanding of the binding
process itself, provides an important contribution to the
concept of selective targeting particular bioactive macro-
molecules in modern molecular medicine. During early-
phase drug development, typically, such in vitro studies
are conducted under closed-system conditions as satur-
ation and competition experiments, which provide quan-
titative parameters for the extent of compound binding
to a target region (e.g. receptor) according to the law of
mass action [1]. In a conventional competitive binding
experiment, the binding of one fixed concentration of a
known radioligand is measured at equilibrium in the
presence of a stepwise increasing series of concentra-
tions of a non-labelled ligand. Data thus obtained are
used to quantify the half-maximum inhibitory concen-
tration (IC50) of the non-labelled ligand [2]. Subse-
quently, the equilibrium inhibitory constant (Ki) can be
calculated using the Cheng-Prusoff transformation [3],
which serves as an indirect parameter for target affinity
of the non-labelled ligand.
In contrast, the binding at equilibrium of an increasing
series of concentrations of a radioligand to a particular
target region is measured in a classical saturation experi-
ment in order to quantify the equilibrium dissociation
constant (Kd) and the concentration of specific binding
sites (BMax) for the radioligand [4]. Since both traditional
in vitro methods belong to dose-dependent assessments,
ligand-receptor binding kinetics is usually overlooked.
Resolving the kinetic mechanisms of biomolecular inter-
actions governing ligand association and dissociation has
become more and more important to improve the per-
formance of binding experiments. Several lines of
research retrospectively suggested that high temporal in-
formation about the binding kinetics can assist to avoid
systematic bias and potential errors of obtained data
under equilibrium and non-equilibrium conditions [5–7].
Furthermore, the validation and interpretation of time-
resolved pharmacokinetic data advance the formulation of
computational methods to analyse biomolecular inter-
actions of ligands with the receptor alone, or even in
combination.
In contrast to in vitro binding studies, in an in vivo
setting, the concentration of a dedicated ligand to its tar-
get region is no longer constant, but changes over time
after administration is often influenced by additional
factors other than basic biomolecular ligand-receptor in-
teractions. Therefore, the in vitro measured Kd alone is
not anymore an informative parameter to characterize
complex compound interactions, as well as in vivo
effectiveness of small molecule drugs, but rather the in
vitro assessment of kinetic parameters such as the
association rate constant (kon) and the dissociation rate
constant (koff ) [8, 9]. As a consequence, various experi-
mental procedures have been introduced to address a
shift from classical affinity-based assessments to kinetic
binding approaches [5, 6, 10–16]. In this context, the
usual practice of performing kinetic binding experiments
is to measure the binding of one or more concentrations
of a radioligand with low nanomolar affinity dedicated
to the target at various time points and determine kon
and koff. With both rate constants, Kd can be calculated
as the ratio of koff/kon [12]. However, the currently avail-
able experimental techniques for the determination of
kinetic binding parameters are time-consuming, labori-
ous and lack the possibility of data acquisition with high
temporal resolution. For that reason, the existing
methods are prone to errors and reduce the scale of
applications in determining biomolecular interactions,
as well as hamper the high-throughput screening of
important binding properties in early-phase drug
discovery [15, 17, 18].
In the present study, we introduce two experimental
approaches for the reliable high-throughput in vitro as-
sessment of binding parameters of both, radiolabelled
and non-labelled compounds, based on high-resolution,
real-time data acquisition of radioligand-receptor bind-
ing kinetics. Herein, we present in competitive real-time
cell-binding studies an experimental assay to determine
the IC50 out of kinetic data in order to calculate the ded-
icated Ki of a non-labelled ligand. Although previously
published work already addressed determination of kon,
koff, Kd, Ki and BMax [19–22], in the present kinetic real-
time cell-binding studies, we established an alternative
experimental design for the assessment of the rate con-
stants kon and koff. Therefore, the observed rate constant
of the association reaction (kob) is used to calculate these
parameters out of different increasing concentrations of
radioligand. The technical principle of the experimental
procedures is based on an equipment technology called
LigandTracer® (Ridgeview Instruments AB, Uppsala,
Sweden), which was successfully established and imple-
mented in a variety of studies dealing with pharmacoki-
netic aspects [23–26]. This technique comprises the
possibility of automated high-resolution real-time
quantification of biomolecular interactions by use of
repeated differential measurements of bound radioli-
gand on cell surface proteins [23]. As a result, we are
capable of following the uptake, retention and dissoci-
ation of a radioligand to its dedicated target region
directly during the experiment.
In the current study, we used the adenosine A3 recep-
tor (A3R) as a sample target to validate the suitability of
the used system and the experimental approaches.
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Adenosine is an important cell modulator and acts as an
endogenous quieting substance via four subtypes of dif-
ferent G-protein-coupled receptors (GPCRs), termed A1,
A2A, A2B and A3 receptors [27, 28]. The A3R is a prom-
ising target for molecular imaging, since it is involved in
many of the body’s cytoprotective functions and changes
of the expression leads to a variety of pathologies, espe-
cially neurological and affective disorders, cardiac
diseases, oncological diseases and inflammation pro-
cesses [29–31]. In this context, the well-known and high
affinity A3R agonist, [
125I]-4-aminobenzyl-5′-N-methyl-
carboxamideoadenosine ([125I]-AB-MECA) was used to
serve as radiolabelled reference compound for both experi-
mental approaches [32, 33]. Commercially available A3R
antagonists, 1,4-dihydro-2-methyl-6-phenyl-4-(phenylethy-
nyl)-3,5-pyridinedicarboxylic acid, 3-ethyl 5-(phenylmethyl)
ester (MRS1191) and 2,3-ethyl-4,5-dipropyl-6-phenylpyri-
dine-3-thiocarboxylate-5-carboxylate (MRS1523) were used
as non-labelled model compounds for the verification of
the competitive real-time cell-binding assay [34–36]. In
addition, six different in-house synthesized A3R antagonists
[37–39] were screened in competitive real-time cell-
binding studies in order to illustrate the feasibility of the
used method. To avoid potential errors and confounding
factors due to the physicochemical properties of the used
compounds, commercially available and in-house
synthesized A3R antagonists were subjected to lipo-
philicity measurements to determine the logarithm of
the octanol-water partition coefficient.
Methods
Cell culture and petri dish preparation
Cell-binding studies were conducted on adherent Chin-
ese hamster ovary cells (CHO-K1) and CHO-K1 cells
stably expressing the human adenosine A3 receptor
(CHO-K1-hA3R). Both cell lines were a generous gift
from Professor Karl-Norbert Klotz (University of Würzburg,
Germany) [40]. CHO-K1 and CHO-K1-hA3R cells were cul-
tured in Ham’s F-12 medium (Gibco®, Life Technologies)
containing 1% penicillin-streptomycin-glutamine (PSG),
10% fetal bovine serum (FBS) and 300 μg/mL Geneticin
(G-418) and incubated in a humidified 5% CO2 atmosphere
at 37 °C. Cells were grown up to 70% confluence in dedi-
cated tissue culture flask (175 cm3, CELLSTAR®, Greiner
Bio-One) and subcultured latest after 2 days to assure
proper cell density, growth and differentiation. The splitting
process was induced by washing the cells with 5 mL
Dulbecco’s phosphate-buffered saline (DPBS) for 10 s
followed by the incubation with 5 mL Trypsin-EDTA for
5 min. Subsequently, the cells were resuspended in 10-mL
cell culture medium, transferred to a 50-mL conical centri-
fugation tube (Greiner Bio-One) and centrifuged at 200g
(1000 rpm) for 5 min. The cell pellet was diluted with 1-mL
medium and spread into a new cell culture flask containing
20 mL Ham’s F-12 medium with additives.
Three days prior to a binding experiment with Ligand-
Tracer®, petri dishes with approximately 106 cells were
prepared (Fig. 1). On the first day, the cells were seeded
as a monolayer on a local part on the bottom of a tilted
cell culture dish (100 mm × 20 mm, CELLSTAR®,
Greiner Bio-One) and incubated with 2-mL medium for
24 h in order to avoid cell migration. On the consecutive
day, the old medium was discarded and the petri dish
was preserved in a horizontal position with 10-mL
medium for additional 24 h. On the third day, the bind-
ing experiment was performed, with fresh medium
(3 mL Ham’s F-12, serum free).
Radioligands and chemical compounds
The radioionated no-carrier-added (n.c.a.) A3R agonist
[125I]-4-aminobenzyl-5′-N-methylcarboxamideoadenosine
([125I]-AB-MECA) was purchased from PerkinElmer®
(PerkinElmer, Inc., Waltham, USA). [125I]-AB-MECA was
described to reveal high affinity (Kd = 0.59 nM) towards
the A3R and used to serve as radiolabelled reference com-
pound with high specific activity (81.4 TBq mmol−1) for
both experimental approaches [32, 33].
A3R antagonists, MRS1191 and MRS1523 were pur-
chased from Sigma-Aldrich (Sigma-Aldrich St. Louis,










SUPPY) and methyl 4,6-diethyl-5-[(methylsulfanyl)carbo-
nyl]-2-phenylpyridine-3-carboxylate ((Me)2@SUPPY) were
synthesized in our department as described previously
[37–39]. All other chemicals were of analytical grade
and purchased from commercial sources.
Measurements of the logarithm of the octanol-water
partition coefficient
The logarithm of the octanol-water partition coefficient
of the A3R antagonists were determined at pH 7.4 by
high-performance liquid chromatography (HPLC)-based
assay (HPLClogD
7.4) modified from Donovan and
Pescatore [41]. Briefly, a mixture of two internal stan-
dards (toluene and triphenylene) with known logD
values and defined retention times (k’) have been used.
A3R antagonists were dissolved in methanol and injected
onto a short polymeric ODP-50 column (20 × 4.0 mm,
5 μm pore size, Supelco, Bellefonte, PA, USA). A linear
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gradient from 10% methanol/90% phosphate buffer
(25 mM, pH 7.4) to 100% methanol within 9.4 min at a
flow rate of 1.5 mL/min were applied. Measurement and
detection of the three retention times of toluene, triphe-
nylene and A3R antagonists were performed at 260 and
285 nm. Between consecutive HPLC runs, 5 min for re-
equilibration of the HPLC column were allowed. The
logD values of the dedicated compounds were deter-
mined using the known logD values of triphenylene and
toluene and the retention time of triphenylene, toluene




   tUnknown þ ttol  logPtriph−ttriph  logPtol
ttol−ttriph
ð1Þ
where “log PUnknown” is the logD value of the test com-
pound and “tUnknown” the corresponding measured re-
tention time of the dedicated substance. The logD values
for the internal standards are abbreviated as “log Ptol”
(toluene) and “log Ptriph” (triphenylene), respectively.
Measured retention times are indicated as “ttol” for tolu-
ene and “ttriph” for triphenylene.
Kinetic real-time cell-binding studies
The assay protocol comprised repeated measurements of
three points of the dedicated area in which the cells
were seeded (cell pole) and three points of the opposing
cell-free area (reference pole) of the petri dish as shown
in Fig. 2a. Target distribution and cell attachment of the
CHO-K1-hA3R cells were monitored continuously dur-
ing the whole course of the binding experiment in the
perimeter trace (Fig. 2b). Raw signal levels from con-
secutive measurements (n = 8) of a representative
experiment after binding equilibrium of 0.7 nM [125I]-
AB-MECA were clearly distinguishable and determined
to be 39.51 ± 0.50, 43.82 ± 0.76 and 38.69 ± 0.52 for the
cell pole and 8.55 ± 0.29, 7.41 ± 0.22 and 10.74 ± 0.52 for
the reference pole, respectively, which is outlined in
Fig. 2b. The corresponding binding trace of the radioli-
gand was calculated as the difference between the aver-
aged values of the cell pole and the reference pole
yielding in a stable background-corrected signal. Kinetic
real-time cell-binding studies were conducted on CHO-
K1-hA3R cells with [
125I]-AB-MECA at ambient
temperature with LigandTracer® Grey. Repeated mea-
surements of the cell pole and the reference pole of the
dedicated petri dishes were performed as shown in
Fig. 2a. The experiments were started with baseline mea-
surements 10–15 min prior radioligand incubation.
Binding of [125I]-AB-MECA to the seeded cells was real-
ized by adding different concentrations (0.05–5 nM) to
fully cover the concentration span needed for proper af-
finity estimation. Each dedicated concentration was in-
cubated separately in a single petri dish, and the
observed rate constants of the association reaction (kobs)
were monitored in real-time until binding equilibrium.
Unspecific uptake of the radioligand on the cell surface
was confirmed with native CHO-K1 cells. As mentioned
previously, the perimeter trace of the LigandTracer® was
used to assure cell viability and attachment.
Competitive real-time cell-binding studies
The measurements were made according to the assay
protocol as previously described above. Competitive
real-time cell-binding studies were performed on CHO-
K1 (negative control) and CHO-K1-hA3R cells in pres-
ence of 0.7 nM [125I]-AB-MECA at ambient temperature
with LigandTracer® Grey (Ridgeview Instruments AB,
Uppsala, Sweden). The experiments were initiated with a
Fig. 1 Schematic illustration of the petri dish preparation. 106 CHO-K1-hA3R cells were seeded on a local part a tilted petri dish and incubated in
2 mL of medium for 24 h (a). On the consecutive day, the petri dish was preserved in a horizontal position and the cells were cultured with 10 mL of
fresh medium for additional 24 h (b). On the third day, the petri dish was subjected to the binding experiment and the cells were provided with 3 mL
of medium without additives (c)
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baseline measurement (10–15 min). Subsequent binding
association of [125I]-AB-MECA was introduced and
continuously observed until binding equilibrium (60–
90 min). Inhibition of the radioligand was performed by
adding different concentration series (1–500 nM) of un-
labelled compounds (A3R antagonists) each after visual
binding equilibrium. At least four different concentra-
tions of competitor, spanning three orders of magnitude
adjusted appropriately for the IC50 of each compound,
were used. Unspecific binding was determined in the
presence of a high concentration (0.5–100 μM) of the
non-labelled competitor substance. The observed associ-
ation phase of the radioligand and the dissociation phase
of each consecutive concentration of the competitor sub-
stance were monitored in real-time until visual binding
equilibrium was reached. All non-labelled compounds
were initially dissolved in DMSO and diluted with deion-
ized water to the final concentration, where the amount of
DMSO never exceeded 5%. Cytophysiological conditions
and cell attachment were examined continuously during
the whole course of the experiment with the perimeter
trace of the LigandTracer® software (version 1.0.1).
Data analysis and statistical procedures
Raw data from the LigandTracer® measurements were
analysed in GraphPad Prism 6.0 (GraphPad Software, Inc.,
San Diego, CA). Experiments were conducted at least as a
triplicate with different batches of radioligand and
biological target material to avoid systematic bias and to
assure statistical certainty. In competitive real-time cell-
binding studies binding association of [125I]-AB-MECA
was transformed to start at time point zero. Transformed
data was analysed using “one-phase association” curve
fitting algorithm as outlined in the following equation:
Y ¼ Y 0 þ Plateau−Y 0ð Þ  1−e−kx
  ð2Þ
where “x” is a given time and “Y” corresponds to the
amount of radioligand binding for a dedicated time point.
“Y0” is the initial value of “Y” at the beginning of radioli-
gand incubation and “plateau” indicates the maximum
amount of the bound radioligand after equilibrium. “k” is
the rate constant expressed in reciprocal units of “x”.
Observed dissociation phases of [125I]-AB-MECA gov-
erned by different concentrations of cold competitor
were transformed to start at time point zero. Trans-
formed data were analysed by using “dissociation—one-
phase exponential decay” curve fit as follows:
Y ¼ Y 0−NSð Þ  e−kx þ NS ð3Þ
where “x” is a given time and “Y” corresponds to the
amount of bound radioligand for a dedicated time point.
“Y0” is the initial value of “Y” at the beginning of each
dissociation phase and “NS” indicates the steady state of
radioligand binding in the presence of dedicated cold
competitor after infinite time. “k” is the rate constant
expressed in reciprocal units of “x”.
Equilibrium binding data determined in Eqs. (2) and
(3) served as input parameters for the calculation of the
IC50 using “log(inhibitor) vs. response—variable slope
(four parameters)” nonlinear regression algorithm as
described below:
Y ¼ Bottom þ Top−Bottomð Þ= 1þ 10 log IC50ð Þ−Cð ÞHillSlopeð Þ
 
ð4Þ
where “C” is the logarithm of the competitor concentra-
tion and “Y” reflects the dedicated amount of bound
radioligand at equilibrium obtained from Eq. (3). “Top”
indicates the maximum amount of radioligand binding
Fig. 2 Representation of the measurement protocol. Real-time binding data of both experimental approaches were acquired according to repeated
measurements of six dedicated reading points on a rotating petri dish (a). Measured points 1, 2 and 6 were located in the cell-free area (reference
pole), whereas 3, 4 and 5 were set on the area in which the cells were seeded (cell pole). Data from each reading point were acquired over 4 s with a
delay of 2 s between successive measurements. The corresponding radioactive signal with respect to the dedicated measurement point
was monitored continuously in the perimeter trace (b). Representative graph from one experiment. Data are shown as mean ± SEM from eight consecutive
measurements at binding equilibrium. If not visible, error bars are within the margin of the symbols
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(without any competitor) whereas the corresponding
value is derived from Eq. (2). “Bottom” expresses the
amount of unspecific radioligand binding in presence of
a very high concentration of competitor. The dedicated
value is determined by Eq. (3) and corresponds to the
“NS” value of the last inhibitor concentration. The “Hill-
Slope” reflects the slope factor, which indicates the
steepness of the resulting inhibition curve. “log(IC50)”
represents the logarithm of the competitor concentra-
tion where 50% of the initial amount of bound radioli-
gand is inhibited. The resulting IC50 was converted into
the Ki using Cheng-Prusoff Eq. (3).
Data of the observed association phases determined
in kinetic real-time cell-binding studies were trans-
formed to start at time point zero. Transformed data
were grouped together and globally fitted by using
“association kinetics—two or more conc. of hot” to
derive a single best-fit estimate for kon and koff as
described as follows:
Y ¼ Ymax  1 −e−kobx ð5Þ
where “x” is a given time and “Y” reflects the amount of
bound radioligand for a dedicated time point. “Ymax”
corresponds to the maximum amount of bound radioli-
gand after equilibrium and “kob” expresses the observed
rate constant of the association reaction.
The observed rate constant of the association reaction
is a function of the dedicated radioligand concentration,
the association rate constant and the dissociation rate
constant, which is described as follows:
kob ¼ kon  Lþ koff ð6Þ
where “kob” is the observed rate constant of the associ-
ation reaction, “kon” represents the association rate con-
stant, “L” reflects the radioligand concentration and
“koff” indicates the dissociation rate constant. Consider-
ing Eqs. (5) and (6), best fit estimations for kon and koff
can be calculated by using multiple radioligand concen-
trations. The resulting rate constants were used to ob-
tain the Kd as the ratio of koff/kon. An estimation of the
target concentration of each single petri dish was derived
by using the following equation:
Ymax ¼ L= Lþ Kdð Þð Þ  Bmax ð7Þ
where “Ymax” is the maximum amount of bound radioli-
gand after equilibrium and “Bmax” reflects the maximum
amount of target receptors. “L” corresponds to the radi-
oligand concentration and “Kd” indicates the affinity of
dedicated radioligand.
Unless mentioned otherwise, all experimental data are
expressed as mean ± SEM as determined by GraphPad
Prism 6 (GraphPad Software, Inc., San Diego, CA) soft-
ware analysis. Descriptive statistical measures were used
to confirm the goodness of the nonlinear regression
models. Differences among groups were proved using
two-tailed, unpaired Student’s t test with Welch’s cor-
rection. Multiple comparisons testing was performed
using either ordinary one-way ANOVA with Tukey’s
correction or ordinary two-way ANOVA with Sidak’s
correction. Values of P < 0.05 were considered as sta-
tistically significant.
Results
Verification of the target distribution and hA3R
expression
Kinetic studies with both CHO-K1 and CHO-K1-hA3R
cells were conducted in a reliable and reproducible man-
ner with high spatial and temporal resolution to verify
specific radiotracer uptake on the dedicated target re-
ceptor (Fig. 3). Differences of the binding association of
[125I]-AB-MECA between CHO-K1 and CHO-K1-hA3R
from three independent experiments were proved to
be statistically significant (P < 0.0001) using two-way
repeated measures ANOVA with Sidak’s multiple
comparisons test.
Measurements of the logarithm of the octanol-water
partition coefficient
Lipophilicity measurements were performed to evaluate
the HPLClogD
7.4 of the A3R antagonists, used in the com-
petitive real-time cell-binding studies. Data were deter-
mined with high reliability and reproducibility and found
to show considerable differences among the dedicated
compounds ranging from 0.97 ± 0.37 up to 4.85 ± 0.01.
Fig. 3 Representative association kinetics of [125I]-AB-MECA. Binding
association of 0.7 nM [125I]-AB-MECA at ambient temperature to CHO-K1-
hA3R cells (a) and to CHO-K1 cells, without the dedicated target receptor
(b). Differences were proved to be statistically significant (P< 0.0001) using
two-way repeated measures ANOVA with Sidak’s multiple comparisons
test. Data are expressed as mean ± SEM from three independent
experiments. If not visible, error bars are within the margin of the symbols
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Compound Structure HPLC logD
7.4 Ki [nM] Ki [nM] Literature
MRS1191 4.83 ± 0.01 42.25 ± 7.28 31.40 ± 2.80 [30]
MRS1523 4.85 ± 0.01 17.75 ± 2.88 18.90 ± 4.10 [32]
FE@SUPPY 4.04 ± 0.36 8.51 ± 1.46 4.22± 0.66 [33]
FE@SUPPY:2 4.05 ± 0.36 8.24 ± 2.35 nd
DFE@SUPPY 0.97 ± 0.37 113.62 ± 16.95 nd
FEMe@SUPPY:2 3.83 ± 0.36 41.24 ± 3.91 nd



















(Me)²@SUPPY 3.66 ± 0.33 46.08 ± 6.66 nd
Displacement of specific [125I]-AB-MECA binding on CHO-K1-hA3R cells at ambient temperature in presence of different A3R antagonists with corresponding
HPLClogD
7.4 parameters. Reported affinity values were determined with traditional binding assays using membranes from human A3R-transfected HEK-293 cells.
Data in the table are expressed as mean ± SEM from three independent experiments
nd not determined
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A detailed summary of the corresponding HPLClogD
7.4
values is shown in Table 1. Data are expressed as
mean ± SEM of three independent experiments, each
performed in triplicate.
Competitive real-time cell-binding studies
An illustration of a representative competitive real-time
cell-binding experiment with [125I]-AB-MECA is shown
in Fig. 4. Binding kinetics of radioligand association and
Fig. 4 Schematic representation of the competitive real-time cell-binding experiment. Association kinetics of 0.7 nM [125I]-AB-MECA at ambient
temperature to CHO-K1-hA3R (a). Association data were fitted in GraphPad Prism 6.0 using “one-phase association”. The value corresponding to
the amount of bound radioligand at equilibrium was obtained using Eq. (2). Consecutive concentration-dependent dissociation kinetics of 0.7 nM
[125I]-AB-MECA in the presence of 2 nM (b), 12 nM (c), 35 nM (d), 100 nM (e) and 500 nM (f) of the A3R antagonist MRS1191, respectively. Dissociation
data were fitted using “dissociation—one-phase exponential decay”. Values of the remaining radioligand binding after equilibrium were obtained from
Eq. (3). The competitive binding curve of [125I]-AB-MECA with MRS1191 (g) was created by means of combination of the equilibrium binding data
obtained in Eqs. (2) and (3). Data were fitted using “log(inhibitor) vs. response—variable slope (four parameters)” nonlinear regression algorithm and
corresponding IC50 values were obtained from Eq. (4). As different concentrations of competitor were used for each individual experiment, data in the
graphs are shown from one representative experiment
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dissociation were obtained with high precision. As a
result, the applied curve fitting algorithms were found to
be highly accurate and revealed values for the coefficient
of determination of 0.9503 ± 0.018 (association phases)
and 0.8136 ± 0.087 (dissociation phases), respectively.
Equilibrium binding data obtained from Eqs. (2) and (3)
were proved to serve as stable input parameters for the
generation of the competitive binding curve and the
associated determination of the IC50. Displacement of
specific [125I]-AB-MECA binding in the presence of dif-
ferent A3R antagonists revealed estimates for the Ki
values as detailed in Table 1. Results from our experi-
ments demonstrate that the inhibitory constants were
varied with respect to modifications on the leaving
groups of the pentasubstituted pyridines, whereas a high
preservation of the chemical structure among com-
pounds were proved to reveal in similar Ki values. Tak-
ing into account the lipophilicity of the tested A3R
antagonists, no influences on the experimental perform-
ance and the resulting affinity were observed. Neverthe-
less, a slight trend was shown, which a decrease of the
logD value is associated with an increasing Ki. Differ-
ences of the inhibitory constants of MRS1191, MRS1523
and FE@SUPPY obtained from our competitive real-
time cell-binding experiments and those previously
reported with membranes from human A3R trans-
fected HEK-293 cells in traditional binding assays
[30, 32, 33] were found to be statistically not signifi-
cant (P > 0.05) using ordinary two-way ANOVA with
Sidak’s correction (Fig. 5).
Kinetic real-time cell-binding studies
Kinetic real-time cell-binding experiments were per-
formed to determine the Kd of the radiolabelled A3R
agonist [125I]-AB-MECA based on the quantification of
the rate constants kon and koff. The observed association
time-courses of the dedicated radioligand concentrations
were obtained with high spatial and temporal resolution
(Fig. 6a). Applied curve fitting algorithms were proved
to be consistent with the measured data points, and
best-fit estimations for kon and koff were determined
using Eqs. (5) and (6) with high reliability and accuracy
(Table 2). To validate these findings, the binding traces
of [125I]-AB-MECA were analysed separately from each
other using one-phase association curve fitting algorithm
and resulting kobs values were plotted against the dedi-
cated radioligand concentration (Fig. 6b). Linear regres-
sion analysis was found to show high correlation (R2 =
0.9927) and revealed values for kon of 8.859 × 10
7 ±
0.299 × 107 M−1 min−1 and for koffof 0.049 ± 0.006 min
−1,
which are in good agreement with the rate constants
obtained from the global fitting approach. To control con-
founding factors due to potential variations of the dedicated
target protein, an assessment of associated hA3R expression
levels was obtained using Eq. (7). Corresponding signal
values were found to confirm homogenous receptor expres-
sion within the whole binding experiment (Fig. 6c). The dif-
ference between the Kd of [
125I]-AB-MECA obtained from
our kinetic binding approach and the binding data as previ-
ously reported in the literature with traditional saturation
binding assays on membranes from human A3R-transfected
HEK-293 cells [29] was proved to be statistically not
significant (P > 0.05) using two-tailed, unpaired Stu-
dent’s t test with Welch’s correction (Fig. 6d). A de-
tailed summary of kon, koff and Kd values are given in
Table 2. Fitting parameters for kon and koff were ob-
tained using a set of eight different concentrations of
[125I]-AB-MECA spanning two orders of magnitude
needed for proper affinity estimation. Reliability and
effectiveness of the experimental approach were
proved by comparing the resulting Kd, determined
using the full set of concentrations, with the corre-
sponding Kd values, calculated from best-fit estima-
tions for the rate constants using two, three, four,
five, six or seven concentrations of the radioligand,
respectively. Differences between Kd values were de-
termined to be statistically not significant (P > 0.05),
using ordinary one-way ANOVA with Tukey’s mul-
tiple comparisons correction (Fig. 7a). Best-fit estima-
tions were found to be less precise when using only a
set of two, three or four concentrations of radioli-
gand. An analysis of the differences between averaged
Kd values revealed that there is a high preservation of
the estimated binding affinity, starting from the usage
of five radioligand concentrations (Fig. 7b).
Fig. 5 Comparison of obtained and reported Ki values. Inhibitory
constants of the A3R antagonists MRS1191, MRS1523 and FE@SUPPY,
respectively, were obtained from competitive real-time cell-binding
studies at ambient temperature with 0.7 nM [125I]-AB-MECA on CHO-
K1-hA3R cells (group A) and compared to the corresponding Ki values
obtained from traditional binding assays, as previously reported in the
literature (group B). Differences for MRS1191, MRS1523 and FE@SUPPY
among groups are statistically not significant (ns = P > 0.05),
using ordinary two-way ANOVA with Sidak’s correction. Data in
the graph are shown as mean ± SEM from three independent
experiments (see Table 1 for summary of dedicated Ki values)
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Discussion
Radioligand-binding studies provide excellent quantita-
tive data with high sensitivity, but are time-consuming,
laborious and lack the possibility of high spatial and
temporal data acquisition [16]. Considering this, the
described approaches improve the determination of
binding kinetics, resulting in a more time-efficient and
comprehensive data acquisition, with high spatial and
temporal resolution. Resolving the kinetic mechanisms
of biomolecular interactions has become more and more
Fig. 6 Graphical representation of the kinetic real-time cell-binding approach. Observed association time-courses of [125I]-AB-MECA to CHO-K1-hA3R at
several concentrations (0.05–5 nM) spanning the Kd (a). Real-time binding data were globally fitted in GraphPad Prism 6.0 using “association kinetics—two
or more conc. of hot” (solid lines). Best-fit estimations for kon and koff were obtained from Eqs. (5) and (6). Resulting rate constants were used to determine
the Kd (see Table 2 for summary of dedicated kon, koff and Kd values). To verify these results, kobs values were determined using Eq. (2) and plotted against
the corresponding concentration of [125I]-AB-MECA (b). Values for kon and koff calculated from linear regression analysis are in good agreement with values
obtained from the global fit estimation. An estimation of the associated target concentration of each single petri dish was used to confirm homogenous
receptor expression within the whole binding experiment (c). Values corresponding to the maximum amount of target receptors were
obtained using Eq. (7). The Kd of [
125I]-AB-MECA obtained from the novel kinetic real-time cell-binding studies and from traditional binding assays, as
previously reported in the literature (see Table 2 for detailed summary of Kd values), was compared using two-tailed, unpaired Student’s t test with Welch’s
correction (d). Differences between the Kd values are statistically not significant (ns = P> 0.05). Data in the graph (a) are shown from one representative
experiment. Data in the graphs (b–d) are shown as mean± SEM from individual experiments (n≥ 4)
Table 2 Best-fit estimations of the rate constants and the resulting Kd values in kinetic real-time cell-binding experiments
Fitting approach kon [M
−1 min−1] koff [min
−1] Kd [nM] R
2 df
2 concentrations 8.675 × 107 ± 0.414 × 107 0.077 ± 0.008 0.887 ± 0.121 0.992 216
3 concentrations 9.262 × 107 ± 0.835 × 107 0.049 ± 0.007 0.528 ± 0.118 0.991 325
4 concentrations 9.243 × 107 ± 0.919 × 107 0.051 ± 0.007 0.556 ± 0.132 0.988 434
5 concentrations 8.805 × 107 ± 0.289 × 107 0.062 ± 0.003 0.704 ± 0.054 0.994 543
6 concentrations 8.788 × 107 ± 0.292 × 107 0.061 ± 0.003 0.695 ± 0.052 0.993 652
7 concentrations 8.105 × 107 ± 0.259 × 107 0.055 ± 0.003 0.683 ± 0.056 0.993 761
8 concentrations 8.068 × 107 ± 0.260 × 107 0.057 ± 0.003 0.711 ± 0.056 0.993 870
Averaged 6.645 × 107 ± 1.423 × 107 0.043 ± 0.014 0.636 ± 0.076 nd nd
Reported affinity nd nd 0.59 ± 0.02 [29] nd nd
Curve fitting parameters of the association rate constant and the dissociation rate constant of [125I]-AB-MECA on CHO-K1-hA3R cells at ambient temperature.
Dedicated Kd values were calculated as the ratio of koff/kon. The table summarizes best-fit estimations and corresponding goodness of fit parameters for a set of
different amount of concentrations of [125I]-AB-MECA. The “averaged” value comprises data from three independent experiments. Reported Kd was determined
with traditional saturation binding assays using membranes from human A3R-transfected HEK-293 cells. Data in the table are expressed as mean ± SEM from individual
experiments (n ≥ 4)
nd not determined
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important to improve the performance of binding exper-
iments and to avoid systematic bias and potential errors
of obtained data under equilibrium and non-equilibrium
conditions [5–7]. This consideration is supported by an
increasing amount of studies, which address a shift from
traditional approaches to the characterization of binding
kinetics [5, 6, 10–16, 22, 23]. In the present study, we
successfully designed and established two experimental
approaches for the reliable in vitro assessment of bind-
ing affinity of both, radiolabelled and non-labelled com-
pounds, based on high-resolution real-time data
acquisition of radioligand-receptor binding kinetics. Re-
alized as competitive real-time cell-binding studies, we
introduced an accurate method for the visualization and
quantification of radioligand dissociation in the presence
of different non-labelled competitor concentrations
(Fig. 4). Time-resolved quantitative data about the kin-
etic mechanisms of the competition, provide information
beyond the fact that competition occurs, including the
relative binding strength or the affinity of the competitor
itself. We determined in our competitive real-time cell-
binding studies the Ki of eight different A3R antagonists
with high reliability (Table 1) and highlighted the suit-
ability of the used method as we confirmed previously
published Ki values of MRS1191, MRS1523 and FE@S-
UPPY (Fig. 5). In addition, we demonstrated that the
experimental performance was not confounded by varia-
tions of the lipophilicity of the tested compounds. In
contrast to in vitro binding experiments, in an in vivo
setting, the concentration of a dedicated ligand to its tar-
get region changes over time and is often influenced by
additional factors other than basic biomolecular ligand-
receptor interactions. As a consequence, the in vitro
measured Kd alone provides not sufficient information
to characterize complex compound interactions and the
potential in vivo effectiveness of small-molecule drugs,
but rather the in vitro assessment of radioligand-
receptor binding kinetics. Furthermore, we successfully
established in kinetic real-time cell-binding studies an
experimental design for the effective and reliable quanti-
fication of the rate constants kon and koff in order to de-
termine the Kd of a radiolabelled ligand. Binding
experiments with the radiotracer [125I]-AB-MECA, a po-
tent A3R agonist, were found to reveal information of
the observed association time courses at various concen-
trations with high spatial and temporal resolution (Fig. 6).
Thus, we determined best-fit estimations for kon and koff
with high reliability and precision, and the resulting Kd
was proved to be in good agreement with the affinity
previously reported with traditional saturation binding
approaches (Table 2; Fig. 6d). In the performance ana-
lysis of the experimental approach, we found that, even
with a low number of radioligand concentrations, an ap-
propriate estimation of the dedicated Kd was possible,
making it suitable for cost-efficient screening of poten-
tial drug candidates. Moreover, we obtained an estima-
tion of the associated hA3R expression levels in order to
control confounding factors due to potential variations
of the dedicated target protein density (6C).
Conclusions
In conclusion, we found that, compared to traditional in
vitro binding assays, the time-resolved kinetic ap-
proaches described in this paper have several advantages
and the practical use is potentially wide. When adding
either the radioligand or the competitor, a steady insight
into association, retention and dissociation of the radi-
olabelled ligand is possible during the experiment with
high spatial and temporal resolution. This information
can be used for the exact determination of binding equi-
librium and provides an increased understanding of the
occasional complex interplay between radiotracer, ligand
Fig. 7 Verification and performance analysis of kinetic-real time cell-binding studies. Best-fit estimations for kon and koff were obtained using Eqs.
(5) and (6), as detailed in the methods, and resulting Kd were calculated as the ratio of koff/kon. Fitted rate constants were determined using eight
different concentrations (0.05–5 nM) of [125I]-AB-MECA to fully cover the concentration span needed for proper affinity estimation. The corresponding Kd (all)
was compared to Kd values, calculated from best-fit estimations for the rate constants using two (2 conc.), three (3 conc.), four (4 conc.), five (5 conc.), six (6
conc.) or seven (7 conc.) concentrations of the radioligand, respectively (a). Differences between the Kd values are statistically not significant (ns = P> 0.05),
using ordinary one-way ANOVA with Tukey’s multiple comparisons correction (see Table 2 for detailed summary of kon, koff and Kd values). Differences
between group means of the dedicated Kd, calculated using the full set of concentrations and the Kd, determined using less concentrations of the
radioligand with the corresponding 95% confidence intervals (b). Data are expressed as mean ± SEM from individual experiments (n≥ 4)
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and the dedicated biological target. Moreover, it has the
potential to facilitate the experimental workflow as it en-
ables interactive intervention, minimizes the quantities
of the used radiotracer and reduces systematic errors
caused by non-equilibrium conditions. In addition, we
found that continuously acquired time-resolved kinetic
data help to improve the computational postprocessing
by providing refined statistical accuracy and advance the
formulation of computational methods to analyse bio-
molecular interactions of ligands with the receptor
alone, or in combination. Both kinetic binding ap-
proaches comprise tracer administration and subsequent
binding to living cells, expressing the dedicated target
protein. Therefore, the experiments are more similar to
the in vivo physiological conditions and provide import-
ant markers of cellular feedback and biological response.
Taken all together, the reliable in vitro assessment of
time-resolved radioligand-receptor binding kinetics has
the potential to provide comprehensive information
to the development of radiolabeled probes for mo-
lecular imaging.
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